Alentis

Alentis develops CLDN1 antibodies for organ fibrosis and tumors, exploring next-gen ADCs and bispecifics to target claudin proteins in cancer.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series C
Initial Investment Year
2023